Company: CSDX
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001214659-25-016410
Chunk: 0

Company: CS DIAGNOSTICS CORP.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
 an integral part of these financial statements.

   6  

CS Diagnostics, Corp.

Condensed Consolidated Statement of Cash Flows

  CS DIAGNOSTICS CORP.                     
  STATEMENT OF CASH FLOWS                  
  FOR THE PERIOD ENDED SEPTEMBER 30, 2025  
  (Unaudited)                              
 ───────────────────────────────────────────

                                                                                 For the Nine Months Ended September 30                                              
                                                                                 2025                                                      2024                      
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Cash flows from operating activities                                                                                                                               
  Net profit/ (loss)                                                                                                           32,081                         4,885  
  Adjustment to reconcile net loss to net cash used in operating activities                                                                                          
  Changes in assets and liabilities                                                                                                                                  
  Other Receivables                                                                                                          ( 31,000                        26,100  
  Account payables                                                                                                            ( 1,609                           893  
  Net cash used in operating activities                                          $                                              ( 528      $                 31,878  
  Cash flows from investing activities                                                                                                                               
  Intangible Asset                                                                                                                                    ( 499,444,401  
  Net cash provided by Investing activities                                                                                                $          ( 499,444,401  
  Cash flows from financing activities                                                                                                                               
  Additional Capital Paid Up                                                                                                                            499,444,401  
  Series C Shares                                                                                                                  40                             -  
  Net cash provided by financing activities                                      $                                                 40      $         499,444,401.00  
  Net increase /(decrease) in cash                                                                                              ( 488                        31,878  
  Cash beginning of period                                                                                                        501                         9,730  
  Cash end of period                                                             $                                                 13      $                 41,608  

The accompanying notes are an integral part of these financial
statements.

   7  

CS Diagnostics, Corp.

Notes to the Financial Statements

September 30, 2025, and December 31, 2024

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

CS
Diagnostics Corp., (the "Company") a Wyoming Corporation in the United State, CS Diagnostics
Corp., is a United States based Corporation, its focus is on improving therapy results and reducing side effects. In addition, it offers
international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MEN